Monitor FDA interactions closely as resolution of the partial clinical hold is critical for U.S. trial progression, while international trial sites continue enrollment. The upcoming 5 mg/kg data readout in Q1 2026 will be a key catalyst.
PEPG drugs
PEPG drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $5.51entry
- T+1 · 9mo ago +3.27%α +4.58% · $5.69
- T+5 · 8mo ago +11.72%α +13.95% · $6.15
- T+20 · 8mo ago −68.57%α −64.79% · $1.73
- T+60 · 6mo ago −73.30%α −84.60% · $1.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PepGen reported financial results for 2025 and provided updates on its PGN-EDODM1 clinical program for myotonic dystrophy type 1. The company announced a partial clinical hold by the FDA on its FREEDOM2 trial due to preclinical pharmacology and toxicology concerns, while also highlighting positive Phase 1 data and ongoing enrollment in international sites. Financially, the company reduced its net loss year-over-year and maintains a strong cash position into 2027.
Key Financial Metrics
Key Facts
- FDA placed a partial clinical hold on the FREEDOM2 Phase 2 trial due to preclinical pharmacology and toxicology data concerns
- Positive Phase 1 FREEDOM trial data showed dose-dependent splicing correction up to 53.7% at 15 mg/kg with generally well-tolerated safety profile
- Company expects data readouts from the 5 mg/kg cohort in Q1 2026 and 10 mg/kg cohort in 2H 2026
- Cash position of $148.5 million as of December 31, 2025, sufficient to fund operations into the second half of 2027
- Net loss decreased to $89.7 million in 2025 from $90.0 million in 2024
Financial Impact
Reduced net loss from $90.0M to $89.7M year-over-year with cash runway extending into 2027
Risk Factors
- FDA partial clinical hold could delay or prevent U.S. clinical development if not resolved
- Safety signals at higher doses (albuminuria) could impact development path
- Dependence on successful clinical trial outcomes for future value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-091503 |
| Document: pepg-20260304.htm | 0001193125-26-091503 |
| Document: pepg-ex99_2.htm | 0001193125-26-091503 |
| Document: 0001193125-26-091503-index-headers.html | 0001193125-26-091503 |
| Document: 0001193125-26-091503-index.html | 0001193125-26-091503 |
| Document: 0001193125-26-091503.txt | 0001193125-26-091503 |
Track record
12 reports on PEPG
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +31.95% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
- May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
- May 12, 202626w ago 8-K Neutral 5/10 Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers